This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Epizyme (EPZM) incurs narrower-than-expected loss in the third quarter of 2018. The company is on track to submit an NDA for tazemetostat in epithelioid sarcoma in the first half of 2019.
Is Eli Lilly and (LLY) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (LLY) Outperforming Other Medical Stocks This Year?
Disney, Michael Kors, Ralph Lauren and Eli Lilly are part of Zacks Earnings Preview
by Zacks Equity Research
Disney, Michael Kors, Ralph Lauren and Eli Lilly are part of Zacks Earnings Preview
Shire's (SHPG) Earnings, Revenues Miss Estimates in Q3
by Zacks Equity Research
Shire (SHPG) misses earnings and revenue estimates in the third quarter of 2018. The company completes the sale of its Oncology franchise in the quarter.
AMAG Posts Wider-Than-Expected Q3 Loss, Beats on Revenues
by Zacks Equity Research
AMAG reports wider than expected loss in the third quarter of 2018. The company completed the sale of Cord Blood Registry in August 2018.
Radius Health (RDUS) Posts Narrower-Than-Expected Q3 Loss
by Zacks Equity Research
Radius Health (RDUS) posts narrower Q3 loss as Tymlos sales gains traction.
Teva (TEVA) Q3 Earnings Beat, 2018 EPS View Up, Shares Rise
by Zacks Equity Research
Teva's (TEVA) shares up 15% despite mixed third-quarter results as it increases its earnings and free cash flow guidance for the full year.
Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus
by Zacks Equity Research
Pfizer (PFE) and Allergan (AGN) report third-quarter results. Eli Lilly (LLY), Pfizer and Sanofi (SNY) announce collaboration deals.
Earnings Estimates Coming Down
by Sheraz Mian
Some areas of weakness have emerged, with companies struggling to beat revenue estimates and a number of leading companies providing underwhelming guidance.
Novo Nordisk (NVO) Reports In-Line Q3 Earnings, Beats Sales
by Zacks Equity Research
Novo Nordisk (NVO) reports in line earnings in the third quarter of 2018 and announces restructuring plans.
Zoetis (ZTS) Beats on Q3 Earnings & Sales, Updates '18 View
by Zacks Equity Research
Zoetis (ZTS) beats both earnings and sales estimates in the third quarter of 2018. The company also updates its 2018 outlook.
United Therapeutics (UTHR) Q3 Earnings Beat but Stock Dips
by Zacks Equity Research
United Therapeutics (UTHR) beats estimates for both earnings and sales in the third quarter but shares sink 10%.
Eli Lilly (LLY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead the company to an earnings beat.
Glaxo (GSK) Beats on Q3 Earnings & Sales, Raises '18 View
by Zacks Equity Research
Glaxo (GSK) beats earnings and sales estimates in the third quarter. Strong sales growth of HIV and respiratory portfolio boosts sales while cost control initiatives aid bottom line.
Eli Lilly (LLY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $108.98, moving +0.59% from the previous trading session.
Sanofi's (SNY) Q3 Earnings and Sales Surpass Estimates
by Zacks Equity Research
Sanofi (SNY) beats on earnings as well as sales in the third quarter of 2018. Sales benefit from the performance of Specialty care segment and recovery in Vaccine segment.
The Pharmaceuticals Industry Stock Outlook: A Steady Path Ahead
by Kinjel Shah
Pipeline success, cost cutting, share buybacks, product launches, increased M&A and collaboration activities are the factors that drives the large-cap pharma industry.
Incyte (INCY) Misses on Q3 Earnings & Revenues, Updates View
by Zacks Equity Research
Incyte (INCY) third-quarter earnings and revenues miss estimates but rise year over year.
Allergan (AGN) Beats on Q3 Earnings, Raises 2018 Guidance
by Zacks Equity Research
Allergan (AGN) beats third-quarter estimates for earnings and sales and raises its full-year guidance for both the metrics. Botox remains the primary sales driver.
Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Hot ETF Right Now?
by Sweta Killa
Smart Beta ETF report for FLQL
This is Why Eli Lilly (LLY) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Teva (TEVA) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.
Merck (MRK) Beats on Q3 Earnings, Lags Sales, Ups EPS View
by Zacks Equity Research
Merck (MRK) beat estimates for earnings while missing the same for sales in third-quarter 2018. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand trends.
J&J Intends to Buy Residual Stake in Japanese Skincare Firm
by Zacks Equity Research
Johnson & Johnson (JNJ) makes a tender offer to buy the leftover stake in Japanese skincare firm Ci:z Holdings for about $2.05 billion in cash to strengthen its dermatology portfolio.